AWM
CRL icon

Apollon Wealth Management’s Charles River Laboratories CRL Stock Holding History

Apollon Wealth Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,454
Closed -$290K – 1420
2025
Q4 		$290K Buy
+1,454
New +$264K 0.01% 1076
2024
Q4 		– Sell
-1,018
Closed -$201K – 1218
2024
Q3 		$201K Buy
+1,018
New +$212K 0.01% 1070
2024
Q2 		– Sell
-1,004
Closed -$272K – 1111
2024
Q1 		$272K Sell
1,004
-283
-22% -$67.6K 0.01% 903
2023
Q4 		$304K Buy
1,287
+255
+25% +$50.1K 0.01% 830
2023
Q3 		$202K Buy
+1,032
New +$212K 0.01% 833
2023
Q2 		– Sell
-1,023
Closed -$206K – 952
2023
Q1 		$206K Sell
1,023
-91
-8% -$20.6K 0.01% 788
2022
Q4 		$243K Buy
+1,114
New +$243K 0.02% 727
2020
Q3 		– Sell
-324
Closed -$56K – 259
2020
Q2 		$56K Buy
+324
New +$51.7K 0.03% 229

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Apollon Wealth Management's CRL Position: Q1 2026 in Review

Apollon Wealth Management sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 1,454 shares — an estimated $290K sold.

Apollon Wealth Management first reported a position in CRL in Q2 2020 and held it in 8 quarters. The position peaked at $304K in Q4 2023. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Apollon Wealth Management reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
  • Apollon Wealth Management sold 1,454 Charles River Laboratories shares in Q1 2026, an estimated $290K.
  • Apollon Wealth Management first reported a position in Charles River Laboratories in Q2 2020 and held it in 8 quarters.
  • Apollon Wealth Management's Charles River Laboratories position peaked at $304K in Q4 2023.
  • 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Apollon Wealth Management's 13F filing for Q1 2026, filed 22 Apr 2026.